vTv Therapeutics

VTVT Rare disease Lead: Phase 3 5 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

Cadisegliatin T1D Ph3 topline2027Cadisegliatin T1D Ph3 topline, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

cadisegliatin

TTP399

Small Molecule Target: glucokinase

Type 1 Diabetes Phase 3 oral NCT03335371
Type 2 Diabetes Phase 2 oral G42 Investments NCT01474083

TTP273

Small Molecule Target: GLP-1 receptor

Cystic Fibrosis-Related Diabetes Phase 2 oral
Type 2 Diabetes Phase 2 oral NCT02653599

TTP-RA

Small Molecule Target: RAGE

Type 1 Diabetes Preclinical oral

mavodelpar

HPP593 · REN001

Small Molecule Target: PPAR-delta

Undisclosed indication

HPP971

Small Molecule Target: Nrf2, Bach1

Undisclosed indication Phase 1

HPP737

Small Molecule Target: PDE4

Undisclosed indication oral Newsoara

Biotech Distilled coverage (5)

2026-08-07 UPDATE: vTv Therapeutics (VTVT) - The Gun They Didn't Fire 🔒 Paid
2026-05-14 UPDATE: vTv Therapeutics (VTVT) – The ATM Refresh on Earnings Day 🔒 Paid
2026-03-29 UPDATE: vTv Therapeutics (VTVT) - Smart Money Buys the Delay
2026-03-14 UPDATE: vTv Therapeutics (VTVT) – A Biotech Delay Hits Phase 3 🔒 Paid
2026-02-04 vTv Therapeutics (VTVT): Scientific Deep Dive for Cadisegliatin and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.